PLCB4 upregulation is associated with unfavorable prognosis in pediatric acute myeloid leukemia

Wu,Shiwen; Zhang,Wei; Shen,Dongqin; Lu,Jianle; Zhao,Li

doi:10.3892/ol.2019.10921

PLCB4 upregulation is associated with unfavorable prognosis in pediatric acute myeloid leukemia

Authors:
- Shiwen Wu
- Wei Zhang
- Dongqin Shen
- Jianle Lu
- Li Zhao
View Affiliations

Affiliations: Department of Clinical Laboratory, The First Hospital of Lanzhou University, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Central Laboratory, The First Hospital of Lanzhou University, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Nursing, The First Hospital of Lanzhou University, Lanzhou University, Lanzhou, Gansu 730000, P.R. China
Published online on: September 25, 2019 https://doi.org/10.3892/ol.2019.10921
Pages: 6057-6065
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phospholipase C (PLC) is a membrane‑associated enzyme that regulates several cellular behaviors including cell motility, growth, transformation and differentiation. PLC is involved in cancer migration, invasion and drug resistance. However, the expression status and prognostic role of PLCB4 in acute myeloid leukemia (AML) remain unclear. In the present study, the complete clinical and mRNA expression data of 285 pediatric patients with de novo AML were obtained from the Therapeutically Available Research to Generate Effective Treatments database. The association between PLCB4 expression and clinical and molecular features was explored. The expression of PLCB4 was significantly higher in patients with AML who relapsed compared with those with long‑term complete remission. Patients with PLCB4 upregulation had significantly lower overall survival (OS) and event free survival (EFS) rate compared with those with low PLCB4 expression. Multivariate Cox's regression analyses demonstrated that high PLCB4 expression was an independent risk factor of adverse OS (P<0.01; HR, 2.081) and EFS (P<0.01; HR, 2.130). Following stratification analysis according to transplant status in cases of first complete remission, the patients with high expression of PLCB4 had significantly lower OS and EFS rate in the chemotherapy group, but not the stem cell transplant group. Furthermore, PLCB4‑associated genes were identified using Spearman's rank correlation analysis. KEGG pathway analysis revealed that PLCB4 and its associated genes were mainly involved in three potential pathways, including the Rap1 signaling pathway. Overall, the findings of the present study suggest that increased PLCB4 expression is associated with poor clinical outcome in pediatric patients with AML, and thus may represent a potential prognostic biomarker and therapeutic target for AML.

View Figures

View References

1	Döhner H, Weisdorf DJ and Bloomfield CD: Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Wang N, Feng YJ, Wang BH, Fang LW, Cong S, Li YC, Yin P, Zhou MG and Wang LH: Disease burden of leukemia in the Chinese population, in 1990 and 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 37:783–787. 2016.(In Chinese). PubMed/NCBI
4	Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–447. 2017. View Article : Google Scholar : PubMed/NCBI
5	Cocco L, Follo MY, Manzoli L and Suh PG: Phosphoinositide-specific phospholipase C in health and disease. J Lipid Res. 56:1853–1860. 2015. View Article : Google Scholar : PubMed/NCBI
6	Follo MY, Manzoli L, Poli A, McCubrey JA and Cocco L: PLC and PI3K/Akt/mTOR signalling in disease and cancer. Adv Biol Regul. 57:10–16. 2015. View Article : Google Scholar : PubMed/NCBI
7	Cheng M, Bhujwalla ZM and Glunde K: Targeting phospholipid metabolism in cancer. Front Oncol. 6:2662016. View Article : Google Scholar : PubMed/NCBI
8	Sengelaub CA, Navrazhina K, Ross JB, Halberg N and Tavazoie SF: PTPRN2 and PLCβ1 promote metastatic breast cancer cell migration through PI(4,5)P2-dependent actin remodeling. EMBO J. 35:62–76. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lo Vasco VR, Calabrese G, Manzoli L, Palka G, Spadano A, Morizio E, Guanciali-Franchi P, Fantasia D and Cocco L: Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 18:1122–1126. 2004. View Article : Google Scholar : PubMed/NCBI
10	Cocco L, Manzoli L, Palka G and Martelli AM: Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia. Adv Enzyme Regul. 45:126–135. 2005. View Article : Google Scholar : PubMed/NCBI
11	Bavelloni A, Poli A, Fiume R, Blalock W, Matteucci A, Ramazzotti G, McCubrey JA, Cocco L and Faenza I: PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. Oncotarget. 5:4222–4231. 2014. View Article : Google Scholar : PubMed/NCBI
12	Bavelloni A, Dmitrienko GI, Goodfellow VJ, Ghavami A, Piazzi M, Blalock W, Chiarini F, Cocco L and Faenza I: PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation. J Cell Physiol. 230:587–594. 2015. View Article : Google Scholar : PubMed/NCBI
13	Bertagnolo V, Benedusi M, Querzoli P, Pedriali M, Magri E, Brugnoli F and Capitani S: PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: A study on tissue microarrays. Int J Oncol. 28:863–872. 2006.PubMed/NCBI
14	Bertagnolo V, Benedusi M, Brugnoli F, Lanuti P, Marchisio M, Querzoli P and Capitani S: Phospholipase C-beta 2 promotes mitosis and migration of human breast cancer-derived cells. Carcinogenesis. 28:1638–1645. 2007. View Article : Google Scholar : PubMed/NCBI
15	Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, et al: Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 7:4624–4631. 2016. View Article : Google Scholar : PubMed/NCBI
16	Li CF, Liu TT, Chuang IC, Chen YY, Fang FM, Chan TC, Li WS and Huang HY: PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget. 8:19997–20010. 2017.PubMed/NCBI
17	Kakiuchi T, Takahara T, Kasugai Y, Arita K, Yoshida N, Karube K, Suguro M, Matsuo K, Nakanishi H, Kiyono T, et al: Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation. Carcinogenesis. Aug 24–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
18	van de Nes JAP, Koelsche C, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Pietsch T, Murali R, Schadendorf D, et al: Activating CYSLTR2 and PLCB4 mutations in primary leptomeningeal melanocytic tumors. J Invest Dermatol. 137:2033–2035. 2017. View Article : Google Scholar : PubMed/NCBI
19	Thomas D and Majeti R: Biology and relevance of human acute myeloid leukemia stem cells. Blood. 129:1577–1585. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
21	Tanabe M and Kanehisa M: Using the KEGG database resource. Curr Protoc Bioinformatics. Chapter 1: Unit1.12. 2012.PubMed/NCBI
22	Aoki KF and Kanehisa M: Using the KEGG database resource. Curr Protoc Bioinformatics. Chapter 1: Unit 1.12. 2005.PubMed/NCBI
23	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
24	Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, et al: Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 17:1086–1093. 2011. View Article : Google Scholar : PubMed/NCBI
25	Zheng GH, Fu JR, Xu YH, Jin XQ, Liu WL and Zhou JF: Screening and cloning of multi-drug resistant genes in HL-60/MDR cells. Leuk Res. 33:1120–1123. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, et al: Assessment of minimal residual disease in standard-Risk AML. N Engl J Med. 374:422–433. 2016. View Article : Google Scholar : PubMed/NCBI
27	Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, et al: High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study. J Clin Oncol. 31:3889–3897. 2013. View Article : Google Scholar : PubMed/NCBI
28	Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, Sandhu VK, Abkowitz JL, Appelbaum FR and Estey EH: Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 33:1258–1264. 2015. View Article : Google Scholar : PubMed/NCBI
29	Schuurhuis GJ and Ossenkoppele G: Minimal residual disease in acute myeloid leukemia: Already predicting a safe haven? Expert Rev Hematol. 3:1–5. 2010. View Article : Google Scholar : PubMed/NCBI
30	Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP, et al: Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 122:1813–1821. 2013. View Article : Google Scholar : PubMed/NCBI
31	Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, et al: Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis. Haematologica. 102:865–873. 2017. View Article : Google Scholar : PubMed/NCBI
32	Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, et al: CD34⁺CD38-leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia. 33:1102–1112. 2018. View Article : Google Scholar : PubMed/NCBI
33	Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, Tigaud I, Pages MP, Chelghoum Y, Baracco F, et al: High frequency of CD34⁺CD38⁻/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World J Stem Cells. 9:227–234. 2017. View Article : Google Scholar : PubMed/NCBI
34	Tomita H, Tanaka K, Tanaka T and Hara A: Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 7:11018–11032. 2016. View Article : Google Scholar : PubMed/NCBI
35	Jaśkiewicz A, Pająk B and Orzechowski A: The many faces of Rap1 GTPase. Int J Mol Sci. 19(pii): E28482018. View Article : Google Scholar : PubMed/NCBI
36	Minato N and Hattori M: Spa-1 (Sipa1) and Rap signaling in leukemia and cancer metastasis. Cancer Sci. 100:17–23. 2009. View Article : Google Scholar : PubMed/NCBI
37	Rebhun JF, Castro AF and Quilliam LA: Identification of guanine nucleotide exchange factors (GEFs) for the Rap1 GTPase. Regulation of MR-GEF by M-Ras-GTP interaction. J Biol Chem. 275:34901–34908. 2000. View Article : Google Scholar : PubMed/NCBI
38	Sot B, Kötting C, Deaconescu D, Suveyzdis Y, Gerwert K and Wittinghofer A: Unravelling the mechanism of dual-specificity GAPs. EMBO J. 29:1205–1214. 2010. View Article : Google Scholar : PubMed/NCBI